(Q45934197)

18 December 2017

title

Levodopa/carbidopa/entacapone in Parkinson's disease. (English)

1 reference

18 December 2017

1 reference

1 reference

2

Robert A Hauser

1 reference

18 December 2017

Lauren C Seeberger

1

1 reference

18 December 2017

publication date

1 July 2009

1 reference

18 December 2017

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

published in

1 reference

18 December 2017

volume

9

1 reference

18 December 2017

issue

7

1 reference

18 December 2017

page(s)

929-940

1 reference

18 December 2017

Projected neurodegenerative disease mortality in the United States, 1990-2040.

cites work

1 reference

Parkinson's disease. First of two parts

21 January 2018

1 reference

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

21 January 2018

1 reference

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

21 January 2018

1 reference

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?

21 January 2018

1 reference

Pathological gambling caused by drugs used to treat Parkinson disease

21 January 2018

1 reference

Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.

21 January 2018

1 reference

Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum

21 January 2018

1 reference

Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa

21 January 2018

1 reference

Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study

21 January 2018

1 reference

Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone

21 January 2018

1 reference

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

21 January 2018

1 reference

Human liver catechol-O-methyltransferase pharmacogenetics

21 January 2018

1 reference

Clinical pharmacokinetics of anti-parkinsonian drugs

21 January 2018

1 reference

Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism

21 January 2018

1 reference

Clinical advantages of COMT inhibition with entacapone - a review

21 January 2018

1 reference

3-O-methyldopa administration does not alter fluorodopa transport into the brain

21 January 2018

1 reference

The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease

21 January 2018

1 reference

Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.

21 January 2018

1 reference

Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique

21 January 2018

1 reference

New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

21 January 2018

1 reference

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

21 January 2018

1 reference

Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose

21 January 2018

1 reference

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

21 January 2018

1 reference

Bimodal administration of entacapone in Parkinson's disease patients improves motor control

21 January 2018

1 reference

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease

21 January 2018

1 reference

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

21 January 2018

1 reference

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

21 January 2018

1 reference

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

21 January 2018

1 reference

Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease

21 January 2018

1 reference

21 January 2018

1 reference

Cross-cultural evaluation of the short form 8-item Parkinson's Disease Questionnaire (PDQ-8): results from America, Canada, Japan, Italy and Spain

21 January 2018

1 reference

Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study

21 January 2018

1 reference

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations

21 January 2018

1 reference

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study

21 January 2018

1 reference

Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study

21 January 2018

1 reference

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease

21 January 2018

1 reference

Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention

21 January 2018

1 reference

Should levodopa dose be reduced when switched to stalevo?

21 January 2018

1 reference

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone

21 January 2018

1 reference

An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off

21 January 2018

1 reference

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of tradi

21 January 2018

1 reference

A quadruple spontaneous dissection of cervicocerebral arteries.

21 January 2018

1 reference

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

21 January 2018

1 reference

The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

21 January 2018

1 reference

Twelve-month safety of entacapone in patients with Parkinson's disease

21 January 2018

1 reference

Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States

21 January 2018

1 reference

Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease

21 January 2018

1 reference

21 January 2018

Antiparkinson prodrugs

1 reference

Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease

21 January 2018

1 reference

New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.09.64

1 reference

18 December 2017

1 reference

18 December 2017